Pharma: Other news to note
Thursday, January 16, 2014
Helsinn Group, of Lugano, Switzerland, said it granted exclusive distribution and licensing rights to Gruppo Angelini SpA, of Rome, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary, Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS countries of its compound in development for anorexia-cachexia syndrome related to non-small-cell lung cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.